and "Tom Abate's reporting on biotechnology has always been ahead of the times. The Biotech Investor tackles the brave new world of stem cells, genomics, and clones and comes up a winner. and " -Thom Calandra, editor in chief, CBS MarketWatchIn The Biotech Investor, San Francisco Chronicle biotechnology reporter Tom Abate explains the science, finances, time horizon, and technological and commercial potential of this burgeoning industry.Abate provides guidelines for assessing company leadership, easy-to-digest reports from the labs, and indispensable investor tools and metrics. He shares strategies foro tracking the effect of breaking news and the NASDAQo anticipating drug trial announcements and FDA approvalso assessing the potential market, patent rights, and distribution deals for a drugHe looks beyond medicine to biotech-related opportunities in everything from agriculture to jean manufacturing to software development. The Biotech Investor is the comprehensive, expert source for successful and intelligent investing in one of the twenty-first century's most promising industries.